Evidence map›Paper›PMID 25216328›Full record

ReviewEndocrine reviews2014

Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors.

Erin E Mulvihill, Daniel J Drucker

2 registry-linked trialsOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Endocrine reviews, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 327 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
327citing papers in PubMed, 6 pooled it
16.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04542213 phase3completednot on this mapstarted 2020, after this paper: background citation

Effect of the Combination of Dipeptidyl Peptidase-4 Inhibitor (DPP4i) and Insulin in Comparison to Insulin on Metabolic Control and Prognosis in Hospitalized Patients With COVID-19

TypeinterventionalSponsorHospital Regional de Alta Especialidad del BajioRan2020 to 2021Enrolled70ConditionsHyperglycemia, Covid19ArmsLinagliptin tablet, Insulin
NCT07241897 phase3not yet recruitingnot on this mapstarted 2025, after this paper: background citation

DPP4 Inhibitor on Post-stroke Cognitive Impairment in Ischemic Stroke Patients With Type 2 Diabetes Mellitus (DISC-DM): Multicentre, Double Blind, Randomised, Placebo Controlled Trial

TypeinterventionalSponsorSecond Affiliated Hospital of Soochow UniversityRan2025 to 2028Enrolled312ConditionsIschemic Stroke, Diabete MellitusArmsSentagliptin Phosphate - single dose, Placebo
3 · Its place in the literature

Who cites it

327 citing papers in PubMed, 6 syntheses or guidelines pooled it, 595 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

267 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Erin E MulvihillDepartment of Medicine, Lunenfeld-Tanenbaum Research Institute, Mt Sinai Hospital, University of Toronto, Toronto, ON M5G 1X5, Canada.
Daniel J Drucker
University of Toronto · CA

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

Dipeptidyl peptidase-4 (DPP4) is a widely expressed enzyme transducing actions through an anchored transmembrane molecule and a soluble circulating protein. Both membrane-associated and soluble DPP4 exert catalytic activity, cleaving proteins containing a position 2 alanine or proline. DPP4-mediated enzymatic cleavage alternatively inactivates peptides or generates new bioactive moieties that may exert competing or novel activities. The widespread use of selective DPP4 inhibitors for the treatment of type 2 diabetes has heightened interest in the molecular mechanisms through which DPP4 inhibitors exert their pleiotropic actions. Here we review the biology of DPP4 with a focus on: 1) identification of pharmacological vs physiological DPP4 substrates; and 2) elucidation of mechanisms of actions of DPP4 in studies employing genetic elimination or chemical reduction of DPP4 activity. We review data identifying the roles of key DPP4 substrates in transducing the glucoregulatory, anti-inflammatory, and cardiometabolic actions of DPP4 inhibitors in both preclinical and clinical studies. Finally, we highlight experimental pitfalls and technical challenges encountered in studies designed to understand the mechanisms of action and downstream targets activated by inhibition of DPP4.

Indexed as

AnimalsClinical Trials as TopicDiabetes Mellitus, Type 2Dipeptidyl Peptidase 4Dipeptidyl-Peptidase IV InhibitorsDisease Models, AnimalHumansMiceSignal TransductionDipeptidyl Peptidase 4Dipeptidyl-Peptidase IV Inhibitors

Identifiers

PMID25216328
PMCPMC7108477
OpenAlexW2131821161

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.